0001181431-14-024372.txt : 20140625
0001181431-14-024372.hdr.sgml : 20140625
20140618160233
ACCESSION NUMBER: 0001181431-14-024372
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140616
FILED AS OF DATE: 20140618
DATE AS OF CHANGE: 20140618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ROUTE 141 & HENRY CLAY ROAD
STREET 2: BUILDING E336
CITY: WILMINGTON
STATE: DE
ZIP: 19880
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: ROUTE 141 & HENRY CLAY ROAD
STREET 2: BUILDING E336
CITY: WILMINGTON
STATE: DE
ZIP: 19880
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levy Richard S
CENTRAL INDEX KEY: 0001454983
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 14928147
MAIL ADDRESS:
STREET 1: EXPERIMENTAL STATION
STREET 2: ROUTE 141 AND HENRY CLAY RD
CITY: WILMINGTON
STATE: DE
ZIP: 19880
4
1
rrd411871.xml
X0306
4
2014-06-16
0
0000879169
INCYTE CORP
INCY
0001454983
Levy Richard S
EXPERIMENTAL STATION
ROUTE 141 AND HENRY CLAY RD
WILMINGTON
DE
19880
0
1
0
0
EVP, Chief Drug Dev&Medical Of
Common Stock
2014-06-16
4
M
0
8000
14.72
A
12301
D
Common Stock
2014-06-16
4
S
0
8000
53.88
D
4301
D
Non-Qualified Stock Option (right to buy)
14.72
2014-06-16
4
M
0
8000
0
D
2018-01-24
Common Stock
8000
76317
D
Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents weighted average sale price. Actual sales prices ranged from $53.44 - $54.32.
Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares.
/s/ Eric Siegel, Attorney In Fact
2014-06-18